Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.
复制标题

获得性免疫缺陷综合征病毒、人类 T 淋巴细胞病毒-III/淋巴结病相关病毒的热灭活,特别是抗血友病因子。

DOI:
10.1172/jci112045
复制
发表时间:
1985
期刊:
The Journal of clinical investigation
影响因子:
--
通讯作者:
B. Evatt
B. Evatt
中科院分区:
--
文献类型:
--
作者:
J.;S. McDougal;L. S. Martin;S. Cort;M. Mozen;C. Heldebrant;B. Evatt

文献摘要

被引文献

相似文献

引起获得性免疫缺陷综合征(艾滋病)的病毒,人类T淋巴细胞嗜性病毒/淋巴结病相关病毒(HTLV-III/LAV),在37℃至60℃的温度下孵育,并通过微培养感染性试验测定病毒滴度(ID-50)随时间的变化。热衰减速率与一级动力学一致,这些数据被用来构建线性Arrhenius图(r = 0.99),用来确定失活时间作为温度的函数。在液体状态下,热衰减受基质(培养基、血清或液体因子VIII)的影响很小。在冻干状态下,在60℃下将病毒滴度降低10倍(1 log)所需的时间为32分钟,而在液体状态下为24秒。HTLV-III/LAV在抗血友病因子VIII或IX液体中冻干并根据商业制造商的规格进行加热。这些方案检测不到传染性病毒。热处理应减少或阻止HTLV-III/LAV通过商业抗血友病因子VIII或IX的传播。
The virus that causes the acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV), was incubated at temperatures from 37 degrees to 60 degrees C and virus titer (ID-50) was determined over time by a microculture infectivity assay. The rate of thermal decay was consistent with first-order kinetics, and these data were used to construct a linear Arrhenius plot (r = 0.99), which was used to determine inactivation time as a function of temperature. In the liquid state, thermal decay was little affected by matrix (culture media, serum, or liquid Factor VIII). In the lyophilized state, the time required to reduce virus titer 10-fold (1 log) at 60 degrees C was 32 min compared with 24 s in the liquid state. HTLV-III/LAV in liquid antihemophilic Factor VIII or IX was lyophilized and heated according to commercial manufacturers' specifications. Infectious virus was undetectable with these regimens. Heat treatment should reduce or stop transmission of HTLV-III/LAV by commercial antihemophilic Factor VIII or IX.